Association of Metformin Use With Risk of Lactic Acido Function

JAMA Internal Medicine

178, 903

DOI: 10.1001/jamainternmed.2018.0292

Citation Report

#	Article	IF	Citations
2	New evidence confirms metforminâ€™s role as first-line therapy with kidney disease. Pharmacy Today, 2018, 24, 23.	0.0	0
3	Lactic Acidosis, Metformin Use, and Dose-Response Association. JAMA Internal Medicine, 2018, 178, 1428.	2.6	1
4	Lactic Acidosis, Metformin Use, and Dose-Response Association. JAMA Internal Medicine, 2018, 178, 1429.	2.6	1
5	Lactic Acidosis, Metformin Use, and Dose-Response Associationâ€”Reply. JAMA Internal Medicine, 2018, 178, 1427.	2.6	3
6	UIAA Medical Commission Recommendations for Mountaineers, Hillwalkers, Trekkers, and Rock and Ice Climbers with Diabetes. High Altitude Medicine and Biology, 2023, 24, 110-126.	0.5	6
7	Lactic Acidosis, Metformin Use, and Dose-Response Association. JAMA Internal Medicine, 2018, 178, 1428.	2.6	0
10	Safety of Metformin in Psoriasis Patients With Diabetes Mellitus: A 17-Year Population-Based Real-World Cohort Study. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3279-3286.	1.8	12
11	Nephro Update Europe 2018. Kidney Diseases (Basel, Switzerland), 2019, 5, 173-181.	1.2	1
12	Changes in the Prescription of Glucoseâ€Lowering Medications in Patients With Type 2 Diabetes Mellitus After a Cardiovascular Event: A Call to Action From the DATAFILE Study. Journal of the American Heart Association, 2019, 8, e012244.	1.6	8
14	Effect of pharmacistâ€led medication review on medication appropriateness in older adults with chronic kidney disease. Journal of Pharmacy Practice and Research, 2019, 49, 471-476.	0.5	6
15	Metformin lactic acidosis: Should we still be afraid?. Diabetes Research and Clinical Practice, 2019, 157, 107879.	1.1	30
16	The Effects of Metformin on Age-Related Changes in the Liver Sinusoidal Endothelial Cell. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2020, 75, 278-285.	1.7	19
17	A new perspective on the biguanide, metformin therapy in type 2 diabetes and lactic acidosis. Journal of Diabetes Investigation, 2019, 10, 906-908.	1.1	12
18	Are patients with mild to moderate renal impairment on metformin or other oral anti-hyperglycaemic agents at increased risk of contrast-induced nephropathy and metabolic acidosis after radiocontrast exposure?. Clinical Radiology, 2019, 74, 651.e1-651.e6.	0.5	4
19	Metformin: time to review its role and safety in chronic kidney disease. Medical Journal of Australia, 2019, 211, 37-42.	0.8	25
21	Inconsistencies in Reporting Studies of Lactic Acidosis. JAMA Internal Medicine, 2019, 179, 455.	2.6	0
22	Inconsistencies in Reporting Studies of Lactic Acidosisâ€”Reply. JAMA Internal Medicine, 2019, 179, 456.	2.6	0
23	Lactic acidosis due to metformin in type 2 diabetes mellitus and chronic kidney disease stage 3â€“5: is it significant?. International Urology and Nephrology, 2019, 51, 1229-1230.	0.6	3

#	Article	IF	Citations
25	Use of non-insulin diabetes medicines after insulin initiation: A retrospective cohort study. PLoS ONE, 2019, 14, e0211820.	1.1	11
26	Therapy of Type 2 Diabetes. Experimental and Clinical Endocrinology and Diabetes, 2019, 127, S73-S92.	0.6	38
27	Recent advances in diabetes treatments and their perioperative implications. Current Opinion in Anaesthesiology, 2019, 32, 398-404.	0.9	26
28	The effect of hospitalization on potentially inappropriate medication use in older adults with chronic kidney disease. Current Medical Research and Opinion, 2019, 35, 1119-1126.	0.9	11
29	Trends in medication utilization, glycemic control and outcomes among type 2 diabetes patients in a tertiary referral center in Singapore from 2007 to 2017. Journal of Diabetes, 2019, 11, 573-581.	0.8	15
30	Reports of Lactic Acidosis Attributed to Metformin, 2015â€“2018. Diabetes Care, 2020, 43, 244-246.	4.3	17
31	Updated guidelines for intravenous contrast use for CT and MRI. Emergency Radiology, 2020, 27, 115-126.	1.0	36
32	A MSN-based tumor-targeted nanoplatform to interfere with lactate metabolism to induce tumor cell acidosis for tumor suppression and anti-metastasis. Nanoscale, 2020, 12, 2966-2972.	2.8	35
33	Metformin and cardiorenal outcomes in diabetes: A reappraisal. Diabetes, Obesity and Metabolism, 2020, 22, 904-915.	2.2	36
34	The FDA Metformin Label Change and Racial and Sex Disparities in Metformin Prescription among Patients with CKD. Journal of the American Society of Nephrology: JASN, 2020, 31, 1847-1858.	3.0	28
35	Dementia Diagnosis Is Associated with Changes in Antidiabetic Drug Prescription: An Open-Cohort Study of â^¼130,000 Swedish Subjects over 14 Years. Journal of Alzheimer's Disease, 2020, 76, 1581-1594.	1.2	11
36	Does metformin do more benefit or harm in chronic kidney disease patients?. Kidney International, 2020, 98, 1098-1101.	2.6	15
37	ASIAN PACIFIC SOCIETY OF NEPHROLOGY CLINICAL PRACTICE GUIDELINE ON DIABETIC KIDNEY DISEASE. Nephrology, 2020, 25, 12-45.	0.7	17
38	Obesity is common in chronic kidney disease and associates with greater antihypertensive usage and proteinuria: evidence from a crossâ€sectional study in a tertiary nephrology centre. Clinical Obesity, 2020, 10, e12402.	1.1	17
39	The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. Nephrology Dialysis Transplantation, 2020, 35, 1700-1711.	0.4	107
40	Metformin Protects against Podocyte Injury in Diabetic Kidney Disease. Pharmaceuticals, 2020, 13, 452.	1.7	11
41	Hospitalization for Lactic Acidosis Among Patients With Reduced Kidney Function Treated With Metformin or Sulfonylureas. Diabetes Care, 2020, 43, 1462-1470.	4.3	22
42	Toxicities Associated With Metformin/Ritonavir Combination Treatment in Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e667-e672.	0.2	6

#	Article	IF	Citations
43	Advances in the management of diabetes: therapies for type 2 diabetes. Postgraduate Medical Journal, 2020, 96, 610-618.	0.9	11
44	Toxicity of Metformin and Hypoglycemic Therapies. Advances in Chronic Kidney Disease, 2020, 27, 18-30.	0.6	16
45	The Long-term Effects of Metformin on Patients With Type 2 Diabetic Kidney Disease. Diabetes Care, 2020, 43, 948-955.	4.3	76
46	In Reply â€" Comparison of Outcomes With Metformin and Sulfonylureas in Chronic Kidney Disease. Mayo Clinic Proceedings, 2020, 95, 1552.	1.4	0
47	Comment on: â€œHigh released lactate by epicardial fat from coronary artery disease patients is reduced by dapagliflozin treatmentâ€. Atherosclerosis, 2020, 296, 2-3.	0.4	5
48	Comment on â€œAssociation of Serum Osmolarity With Contrast-Induced Nephropathy in Patients With ST-Segment Elevation Myocardial Infarctionâ€. Angiology, 2020, 71, 669-670.	0.8	0
49	Incidence and associates of diabetic ketoacidosis in a community-based cohort: the Fremantle Diabetes Study Phase II. BMJ Open Diabetes Research and Care, 2020, 8, e000983.	1.2	12
50	Adjunctive metformin for antipsychotic-induced dyslipidemia: a meta-analysis of randomized, double-blind, placebo-controlled trials. Translational Psychiatry, 2020, 10, 117.	2.4	23
52	Effect of continuous use of metformin on kidney function in diabetes patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. BMC Cardiovascular Disorders, 2020, 20, 187.	0.7	9
53	Long-term efficacy and safety of anti-hyperglycaemic agents in new-onset diabetes after transplant: Results from outpatient-based 1-year follow-up and a brief review of treatment options. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2021, 15, 13-19.	1.8	3
54	Glucoseâ€lowering pharmacotherapies in Chinese adults with type 2 diabetes and cardiovascular disease or chronic kidney disease. An expert consensus reported by the Chinese Diabetes Society and the Chinese Society of Endocrinology. Diabetes/Metabolism Research and Reviews, 2021, 37, e3416.	1.7	7
55	Lactic acidosis incidence with metformin in patients with type 2 diabetes and chronic kidney disease: A retrospective nested caseâ€control study. Endocrinology, Diabetes and Metabolism, 2021, 4, e00170.	1.0	8
56	Metformin use in patients with type 2 diabetes mellitus and chronic kidney disease: An evidence-based review. Annals of the Academy of Medicine, Singapore, 2021, 50, 159-170.	0.2	1
57	DIAGNOSIS OF ENDOCRINE DISEASE: Post-pancreatitis diabetes mellitus: prime time for secondary disease. European Journal of Endocrinology, 2021, 184, R137-R149.	1.9	52
60	Mechanism and application of metformin in kidney diseases: An update. Biomedicine and Pharmacotherapy, 2021, 138, 111454.	2.5	44
61	Dashboards to reduce inappropriate prescribing of metformin and aspirin: A quality assurance programme in a primary care sentinel network. Primary Care Diabetes, 2021, 15, 1075-1079.	0.9	2
62	Safety and effectiveness of metformin in patients with reduced renal function: A systematic review. Diabetes, Obesity and Metabolism, 2021, 23, 2035-2047.	2.2	7
63	Management of type 2 diabetes in chronic kidney disease. BMJ Open Diabetes Research and Care, 2021, 9, e002300.	1.2	12

#	Article	IF	Citations
64	Things We Do For No Reasonâ„¢: Routinely Holding Metformin in the Hospital. Journal of Hospital Medicine, 2021, , .	0.7	2
65	Association of metformin use on metabolic acidosis in diabetic patients with chronic hepatitis Bâ€related cirrhosis and renal impairment. Health Science Reports, 2021, 4, e352.	0.6	1
66	Fabrication of antioxidative and antibacterial surface coatings with metformin-loaded self-assembled multilayers for periodontal regeneration in diabetes mellitus patients. Journal of Materials Science, 2021, 56, 18668-18683.	1.7	5
67	Metformin, chronic nephropathy and lactic acidosis: a multi-faceted issue for the nephrologist. Journal of Nephrology, 2021, 34, 1127-1135.	0.9	19
68	Acidosis lÃ¡ctica asociada a metformina, Â¿un fantasma o un asesino?. Revista Clinica Espanola, 2019, 219, 256-257.	0.2	2
70	Kidney Disease Management in the Hospital Setting: A Focus on Inappropriate Drug Prescriptions in Older Patients. Frontiers in Pharmacology, 2021, 12, 749711.	1.6	8
71	Should metformin be used in every patient with type 2 diabetes?. Cleveland Clinic Journal of Medicine, 2019, 86, 17-20.	0.6	3
72	Therapeutic Options for Management of Diabetic Nephropathy. Nephrology Self-assessment Program: NephSAP, 2019, 18, 220-223.	3.0	0
73	Metformin for preventing the progression of chronic kidney disease. The Cochrane Library, 0, , .	1.5	0
74	La era del big data: anÃ¡lisis del lenguaje natural mediante la aplicaciÃ³n de folksonomÃa. Nefrologia, 2022, 42, 680-687.	0.2	1
75	Insight Into the Perioperative Management of Type 2 Diabetes. Cureus, 2020, 12, e6878.	0.2	4
76	Lactic acid induces fibroblast growth factor 23 (FGF23) production in UMR106 osteoblast-like cells. Molecular and Cellular Biochemistry, 2022, 477, 363-370.	1.4	5
77	Recommendations for Practical Use of Metformin, a Central Pharmacological Therapy in Type 2 Diabetes. Clinical Diabetes, 2022, 40, 97-107.	1.2	3
78	Continuous use of metformin in patients receiving contrast medium: what is the evidence? A systematic review and meta-analysis. European Radiology, 2022, 32, 3045-3055.	2.3	1
79	Drug Therapies Affecting Renal Function: An Overview. Cureus, 2021, 13, e19924.	0.2	3
80	Metformin-associated lactic acidosis exacerbated by acute kidney injury in an overseas traveler. CEN Case Reports, 2021, , 1.	0.5	2
81	Sex-specific effects of metformin and liraglutide on renal pathology and expression of connexin 45 and pannexin 1 following long-term high-fat high-sugar diet. Acta Histochemica, 2021, 123, 151817.	0.9	2
82	Focal brain lactate accumulation in metformin-induced encephalopathy without systemic lactic acidosis: A case report suggesting mitochondrial vulnerability in lentiform fork sign. ENeurologicalSci, 2021, 25, 100383.	0.5	3

#	Article	IF	Citations
83	Century of Evolution of Non-Insulin Therapeutic Options in Management of Diabetes. Journal of Diabetes Mellitus, 2021, 11, 305-316.	0.1	1
84	Association of Metformin Use With Risk of Venous Thromboembolism in Adults With Type 2 Diabetes: A General-Populationâ€“Based Cohort Study. American Journal of Epidemiology, 2022, 191, 856-866.	1.6	2
85	A Comparative Study of Acidosis in Diabetic Advanced Chronic Kidney Disease Patients on and off Metformin. Cureus, 2022, 14, e21291.	0.2	0
86	Clinical practice guidelines for management of hyperglycaemia in adults with diabetic kidney disease. British Journal of Diabetes, 0, , .	0.1	0
87	Clinical practice guidelines for management of hyperglycaemia in adults with diabetic kidney disease. Diabetic Medicine, 2022, 39, e14769.	1.2	10
88	KDOQI US Commentary on the KDIGO 2020 Clinical Practice Guideline for Diabetes Management in CKD. American Journal of Kidney Diseases, 2022, 79, 457-479.	2.1	18
89	Metforminâ€™s Mechanism of Action Is Stimulation of the Biosynthesis of the Natural Cyclic AMP Antagonist Prostaglandylinositol Cyclic Phosphate (Cyclic PIP). International Journal of Molecular Sciences, 2022, 23, 2200.	1.8	5
90	Metformin induces lactate accumulation and accelerates renal cyst progression in Pkd1-deficient mice. Human Molecular Genetics, 2022, 31, 1560-1573.	1.4	11
91	Ameliorating Metabolic Profiles After Kidney Transplantation: A Protocol for an Open-Label, Prospective, Randomized, 3-Arm, Controlled Trial. Frontiers in Medicine, 2021, 8, 800872.	1.2	1
92	Management of Hyperglycemia in Older Adults with Type 2 Diabetes. Drugs and Aging, 2022, 39, 39-58.	1.3	5
93	Relationship between metformin use and lactic acidosis in advanced chronic kidney disease: The REMIND-TMU study. American Journal of the Medical Sciences, 2022, 364, 575-582.	0.4	3
95	Therapy of Type 2 Diabetes. Experimental and Clinical Endocrinology and Diabetes, 2022, 130, S80-S112.	0.6	5
96	Effects of Oral Glucose-Lowering Agents on Gut Microbiota and Microbial Metabolites. Frontiers in Endocrinology, 0, 13, .	1.5	9
97	Drugs in Clinical Development to Treat Autosomal Dominant Polycystic Kidney Disease. Drugs, 2022, 82, 1095-1115.	4.9	12
98	The influence of metformin transporter gene SLC22A1 and SLC47A1 variants on steady-state pharmacokinetics and glycemic response. PLoS ONE, 2022, 17, e0271410.	1.1	2
99	Attenuated Risk Association of End-Stage Kidney Disease with Metformin in Type 2 Diabetes with eGFR Categories 1â€“4. Pharmaceuticals, 2022, 15, 1140.	1.7	7
100	Hemato-biochemical indices alteration, oxidative stress, and immune suppression in the African catfish (Clarias gariepinus) exposed to metformin. Toxicology and Environmental Health Sciences, 2022, 14, 361-369.	1.1	2
101	Shouldn't Stage 4 And 5 Chronic Kidney Disease Patients Use Metformin?. KahramanmaraÅŸ SÃ¼tÃ§Ã¼ Ä°mam Ãœniversitesi TÄ±p FakÃ¼ltesi Dergisi, 0, , .	0.1	0

#	Article	IF	Citations
102	Metformin and Acute Kidney Injury: Recipe for Disaster. , 2022, 1, 13-15.		0
103	Drugâ€“drug interactions involving combinations of antipsychotic agents with antidiabetic, lipid-lowering, and weight loss drugs. Expert Opinion on Drug Metabolism and Toxicology, 2022, 18, 729-744.	1.5	1
104	Metformin in therapeutic applications in human diseases: its mechanism of action and clinical study. Molecular Biomedicine, 2022, 3, .	1.7	19
105	The Effectiveness and Safety of Metformin Compared to Sulfonylureas in Diabetic Nephropathy: A Systematic Review. Cureus, 2022, , .	0.2	0
106	Use of Classes of Antihyperglycemic Agents in People With Type 2 Diabetes Based on Level of Estimated Glomerular Filtration Rate. Canadian Journal of Diabetes, 2023, , .	0.4	0
107	The big data era: The usefulness of folksonomy for natural language processing. Nefrologia, 2022, 42, 680-687.	0.2	0
108	Metformin Suppresses Thioacetamide-Induced Chronic Kidney Disease in Association with the Upregulation of AMPK and Downregulation of Oxidative Stress and Inflammation as Well as Dyslipidemia and Hypertension. Molecules, 2023, 28, 2756.	1.7	0
109	Risk of Lactic Acidosis in Hospitalized Diabetic Patients Prescribed Biguanides in Japan: A Retrospective Total-Population Cohort Study. International Journal of Environmental Research and Public Health, 2023, 20, 5300.	1.2	0
110	Diabetic Kidney Disease. Medical Clinics of North America, 2023, 107, 689-705.	1.1	12